Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

Author：                      

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.6, 2015-01, pp. : 1208-1212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study

By Kamiya Naoto   Suzuki Hiroyoshi   Ueda Takeshi   Sato Naohide   Nakatsu Hiroomi   Mikami Kazuo   Sato Nobuo   Nomura Kazushi   Akakura Koichiro   Okano Tatsuya   Ooki Takemasa   Naya Yukio   Ota Sho   Masai Motoyuki   Ichikawa Tomohiko  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 157-164

Springer Publishing Company

Access to resources Recommend Favorite

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

By Sternberg C. N.   Molina A.   North S.   Mainwaring P.   Fizazi K.   Hao Y.   Rothman M.   Gagnon D. D.   Kheoh T.   Haqq C. M.   Cleeland C.   de Bono J. S.   Scher H. I.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1017-1025

Oxford University Press

Access to resources Recommend Favorite

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

By Jochems Caroline   Tucker Jo   Tsang Kwong-Yok   Madan Ravi   Dahut William   Liewehr David   Steinberg Seth   Gulley James   Schlom Jeffrey  

Cancer Immunology, Immunotherapy, Vol. 63, Iss. 4, 2014-04 ,pp. : 407-418

Springer Publishing Company

Access to resources Recommend Favorite

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)

By Meulenbeld Hielke   Bono Johann   Tagawa Scott   Whang Young   Li Xiaoyun   Heath Karl   Zandvliet Anthe   Ebbinghaus Scot   Hudes Gary   Wit Ronald  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 909-916

Springer Publishing Company

Access to resources Recommend Favorite

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer

By                  

Experimental and Therapeutic Medicine, Vol. 2, Iss. 4, 2011-01 ,pp. : 579-584

Spandidos Publications

Access to resources Recommend Favorite